Q3 EPS Forecast for Acrivon Therapeutics Boosted by Analyst

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Equities researchers at HC Wainwright increased their Q3 2025 earnings per share estimates for shares of Acrivon Therapeutics in a report released on Thursday, May 15th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($0.52) per share for the quarter, up from their previous forecast of ($0.53). HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.12) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($2.52) EPS, FY2028 earnings at ($1.93) EPS and FY2029 earnings at ($1.24) EPS.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.06.

Several other equities analysts have also recently issued reports on ACRV. Cantor Fitzgerald restated an “overweight” rating on shares of Acrivon Therapeutics in a research report on Wednesday, March 26th. Oppenheimer lowered their target price on shares of Acrivon Therapeutics from $10.00 to $9.00 and set an “outperform” rating on the stock in a research report on Thursday. KeyCorp started coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They set an “overweight” rating for the company. Jones Trading reiterated a “hold” rating on shares of Acrivon Therapeutics in a report on Friday. Finally, Piper Sandler initiated coverage on shares of Acrivon Therapeutics in a research note on Monday, May 5th. They issued an “overweight” rating and a $6.00 target price for the company. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $17.71.

Acrivon Therapeutics Price Performance

Shares of ACRV opened at $1.15 on Monday. Acrivon Therapeutics has a 1-year low of $1.09 and a 1-year high of $10.16. The stock has a market cap of $36.06 million, a PE ratio of -0.43 and a beta of 1.88. The firm has a fifty day moving average price of $2.36 and a 200 day moving average price of $4.93.

Insider Buying and Selling

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc sold 215,283 shares of the stock in a transaction on Monday, April 28th. The stock was sold at an average price of $1.56, for a total transaction of $335,841.48. Following the completion of the transaction, the insider now directly owns 4,090,906 shares in the company, valued at $6,381,813.36. This represents a 5.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders sold 1,707,833 shares of company stock valued at $3,009,858. Insiders own 11.90% of the company’s stock.

Hedge Funds Weigh In On Acrivon Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC bought a new stake in shares of Acrivon Therapeutics during the fourth quarter worth $2,440,000. Wealthedge Investment Advisors LLC increased its stake in shares of Acrivon Therapeutics by 420.1% during the 1st quarter. Wealthedge Investment Advisors LLC now owns 56,467 shares of the company’s stock worth $115,000 after purchasing an additional 45,610 shares during the last quarter. Invesco Ltd. bought a new stake in Acrivon Therapeutics in the first quarter valued at approximately $72,000. JPMorgan Chase & Co. raised its stake in Acrivon Therapeutics by 548.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 33,991 shares of the company’s stock valued at $238,000 after acquiring an additional 28,748 shares during the period. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Acrivon Therapeutics by 29.7% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,784 shares of the company’s stock worth $619,000 after buying an additional 23,535 shares during the last quarter. Institutional investors own 71.62% of the company’s stock.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.